We report the results of a phase III trial comparing tacrolimus (FK506) with cyclosporine for GVHD prophylaxis after allogeneic BMT. From February 1995 to July 1996, 136 patients were enrolled and followed up to September 1997. During the first 100 days posttransplant the incidence of grade II-IV acute GVHD (the primary end-point) was lower in the tacrolimus group (17.5%) compared with the cyclosporine group (48.0%, P Ͻ 0.0001). A significant difference was observed between the tacrolimus and cyclosporine groups when subset analyses were performed based on recipients from HLA-matched siblings (13.3% vs 41.3%, P = 0.015) or donors other than HLA-matched siblings (21.4% vs 53.8%, P = 0.0029). The incidence of chronic GVHD (47.3% and 47.8%) and Kaplan-Meier estimate of overall survival (62.9% and 65.2%) were similar between the tacrolimus and cyclosporine groups, respectively. The overall leukemia relapse rate was not significantly different between the tacrolimus and cyclosporine groups (19.6% and 11.4%, respectively). However, the relapse rate among recipients from HLAmatched siblings was significantly higher in the tacrolimus group (30.9%) compared with the cyclosporine group (3.6%, P = 0.013). These results suggest the merit of tacrolimus for the prophylaxis of acute GVHD, but a lack of merit for a graft-versus-leukemia effect among recipients from HLA-matched sibling donors. Bone Marrow Transplantation (2001) 28, 181-185.
Acute GVHD is a common immunological complication of allogeneic BMT, occurring in 40% to 50% of recipients. Prevention of GVHD is a critical factor in transplant-related morbidity and mortality, and has been a major target of research efforts in allogeneic BMT for the past two decades. Currently, the combination of cyclosporine and shortcourse methotrexate is the standard prophylactic regimen used in most medical institutions.
Tacrolimus or FK506, a potent macrolide lactone immunosuppressant, was originally isolated from the soil fungus Streptomyces tsukubaensis, in 1985, 1, 2 and was initially introduced into clinical trials for the prevention of rejection in recipients of solid-organ transplants. 3 In animal models tacrolimus has been shown to be effective in the prevention of acute GVHD, [4] [5] [6] and, when used in combination with methotrexate, a better outcome was obtained than with tacrolimus alone. 7 Since the efficacy of tacrolimus for the treatment and prevention of acute GVHD has been reported in several phase II studies, [8] [9] [10] [11] we conducted this randomized clinical trial to compare tacrolimus with cyclosporine for the prevention of acute GVHD in allogeneic BMT recipients.
Patients and methods

Patient eligibility
Male and female patients who were scheduled for their first T cell-repleted allogeneic BMT were considered for enrollment in this study. Eligible patients had not received anti-lymphocyte or anti-thymocyte globulin. Patients were excluded from the study if they had any severe impairment of renal, hepatic, or pulmonary function, or any history of serious cardiac disease, hypertension, pancreatitis, hyperkalemia, or diabetes mellitus. Pregnant or lactating patients were not eligible for the study. Patients were excluded if they had any infection including hepatitis B and C, syphilis or HIV. Each eligible patient signed an informed consent approved by the Institutional Review Board at their institution.
Study design
The primary endpoint of this study was the incidence of grade II-IV acute GVHD during the first 100 days posttransplant, analyzed on an intent-to-treat basis. The secondary endpoints were engraftment, incidence of chronic GVHD, overall survival, and leukemia relapse. This study was designed as an open-label, randomized, parallel group comparison study using the dynamic allocation method. For dynamic patient allocation, the minimization method was used to minimize imbalance between the tacrolimus and cyclosporine groups in each of the medical institutions, and the imbalance with respect to each of the following three prognostic factors: recipient age (Ͻ16, у16-Ͻ40, у40 years), donor-recipient relation (HLA-matched siblings, donors other than HLA-matched siblings), and underlying disease and disease status. An Evaluation Committee was established to standardize and objectively examine, in a blinded manner, the items related to clinical assessment such as patient eligibility and the appropriateness of GVHD diagnosis.
Treatment protocol
Preparative regimens and supportive care was assigned according to the institutional protocols at each medical institution, and were uniformally applied to the patients in both treatment groups. Either tacrolimus or cyclosporine was initiated on day −1 of transplantation. The starting dose of tacrolimus was either 0.075 mg/kg p.o. twice a day or 0.05 mg/kg/day by continuous i.v. infusion over 24 h. The target trough level was determined as 20-25 ng/ml for a 2-to 3-week period after transplantation and 10-15 ng/ml thereafter. Whole blood trough levels of tacrolimus and cyclosporine were measured by the EIA method and the RIA method using monoclonal antibody, respectively, three times a week for the period up to 4 weeks post-transplant, once a week up to 100 days post-transplant, and monthly thereafter. In principle, the study drugs were administered orally. The route of administration was changed from oral to intravenous for any patient unable to tolerate oral intake. The dose and route of administration of cyclosporine, and the concomitant use of immunosuppressants (methotrexate or steroid) in addition to tacrolimus or cyclosporine were determined by each medical institution, based on their routine regimen.
Grading of GVHD
The severity of acute GVHD was graded by the investigators at each medical institution using the consensus criteria. 12 Tissue biopsy samples were obtained to confirm the diagnosis of acute GVHD whenever clinically feasible. The diagnosis and grading of chronic GVHD were established according to accepted clinical and pathologic criteria. 13 
Statistical analysis
To test the balance of patients' background factors between two groups, the chi-square test, Fisher's exact test and the Mann-Whitney U-test were applied according to the scale and properties of variables. The Kaplan-Meier method was used to calculate the estimates of the cumulative incidence of acute and chronic GVHD, overall survival rate and leukemia relapse rate. The log-rank test was used to compare the cumulative incidence between groups. All P values were two-sided and a value of Ͻ0.05 was considered statistically significant.
Results
Patient characteristics
From February 1995 to July 1996, 136 patients were enrolled from 26 medical institutions participating in the FK506 (tacrolimus) Bone Marrow Transplantation Study Group, and followed up to September 1997. A median of four patients (range, 1-20 patients) were enrolled from each institution. Three of the 136 patients enrolled (one in the tacrolimus group and two in the cyclosporine group) withdrew consent prior to receiving study drug and were excluded from all analyses. Of the remaining 133 patients, 67 were randomized to receive tacrolimus and 66 to receive cyclosporine. One patient in the tacrolimus group who developed itching and erythema at the preliminary testing, performed 8 days before transplantation, and one patient in the cyclosporine group who was found to be HBsAg-positive after the start of administration, were excluded from the study. There were no statistical differences between the two treatment groups in any of the three prognostic factors: age, donor-recipient relation, and underlying disease and disease status (Table 1) .
Acute GVHD
Six patients in the tacrolimus group and one patient in the cyclosporine group received only the study drug. Fifty-six patients in each treatment group received concomitant short-term methotrexate and the remaining patients received steroids concomitantly with the study drug. The cumulative incidence of grade II-IV acute GVHD during the first 100 days after transplantation in the tacrolimus and cyclosporine groups were 17.5% and 48.0%, respectively (P Ͻ 0.0001, Figure 1a) . The results of subgroup analysis on donor type showed that the cumulative incidence of grade II-IV acute GVHD was significantly lower in the tacrolimus group compared with the cyclosporine group, not only among recipients from HLA-matched siblings (Figure 1b) , but also among recipients from other donors (Figure 1c) . The cumulative incidence of grade III-IV acute GVHD was 9.5% in the tacrolimus group and 21.1% in the cyclosporine group (P = 0.073).
Engraftment
There was no statistical difference between the two treatment groups with respect to the cumulative incidence rate Bone Marrow Transplantation of restoration of bone marrow function 100 days after transplantation (WBC, P = 0.48; neutrophil, P = 0.90; platelet, P = 0.60). Specifically, the median number of days required to achieve of the WBC count to у1 × 10 9 /l, the neutrophil count to у0.5 × 10 9 /l and the platelet count to у50 × 10 9 /l were 19, 19, and 28.5 in the tacrolimus group, and 18, 17, and 30 in the cyclosporine group, respectively.
Adverse drug reactions
Adverse drug reactions were observed in 31.3% of the tacrolimus group and 18.2% of the cyclosporine group, respectively (P = 0.12). The major adverse drug reactions encountered were hypertension, numbness and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura syndrome in the tacrolimus group and hypertension in the cyclosporine group. Abnormal laboratory test findings were obtained in 68.7% of the patients in the tacrolimus group and in 47.0% of the patients in the cyclosporine group, respectively (P = 0.018). The most frequently reported abnormal laboratory test findings involved renal function parameters, hyperkalemia, abnormal glucose tolerance and hypomagnesemia. No patient required hemodialysis. Within 100 days post-transplant, study drug was discontinued in 27 patients in the tacrolimus group and 25 patients in the cyclosporine group.The main reasons for discontinuation were adverse drug reactions and abnormal laboratory test findings in the tacrolimus group (n = 14), and progression of acute GVHD in the cyclosporine group (n = 10).
Follow-up data
The cumulative incidence of chronic GVHD was 47.3% in the tacrolimus and 47.8% in the cyclosporine group (P = 0.77). The cumulative survival rate at the final observation was 62.9% in the tacrolimus group and 65.2% in the cyclo- sporine group, (P = 0.93, Figure 2a) . In subset analyses, there was no significant difference in survival rates between the tacrolimus and cyclosporine groups, when analyzed among recipients from HLA-matched siblings (55.5% and 73.0%, respectively, P = 0.24, Figure 2b ) or among recipients from other donors (70.6% and 58.0%, respectively P = 0.36, Figure 2c ). The cumulative relapse rate at final observation was 19.6% in the tacrolimus group and 11.4% in the cyclosporine group, respectively (P = 0.30, Figure  3a) . Figures 3b and 3c show the cumulative relapse rate analyzed by donor type. Relapse rate was significantly higher in the tacrolimus group (30.9%) compared with the cyclosporine group (3.6%, P = 0.013) among recipients from HLA-matched siblings (Figure 3b ).
Discussion
The results of this study confirm the efficacy of tacrolimus and suggest the superiority of tacrolimus over cyclosporine for the prevention of moderate to severe acute GVHD in recipients from HLA-matched sibling donors and also recipients from donors other than HLA-matched siblings, as observed in other randomized studies.
14,15 There was a significant difference in the incidence of abnormal laboratory test findings between the two treatment groups, favoring cyclosporine. There was no difference in the incidence of discontinuation between the two groups, but the main reason for discontinuation was quite different, being adverse drug reactions/abnormal laboratory test findings in the tacrolimus group and progression of acute GVHD in the cyclosporine group. Fluctuation in the blood level of tacrolimus was considered a major contributing factor for the reported adverse drug reactions/abnormal laboratory test findings. Careful monitoring of blood levels might significantly improve the safety profile for tacrolimus.
There was no significant difference in survival rate between the two treatment groups. With regard to the overall relapse rate, there was no significant difference between the treatment groups. However, relapse rate among recipients from HLA-matched siblings was significantly higher in the tacrolimus group, compared with the cyclosporine group. It is possible that tacrolimus might have adversely influenced the GVL effect, although the relapse rate of cyclosporine-treated recipients from HLA-matched siblings in this study was lower than the relapse rate reported among Japanese recipients in other studies. 16, 17 The incidence of relapse differs depending on the primary disease and its stage. The GVL effect also differs depending on the primary disease. 18 Thus, a more detailed subgroup analysis involving a larger number of patients would be necessary.
These results suggest the merit of tacrolimus for the prophylaxis of acute GVHD, but lack of merit for a GVL effect among recipients from HLA-matched sibling donors.
